ArticleJournal of neuro-oncology2016
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.Neuro-oncology · 2023Article
- Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy.Journal of clinical medicine · 2022Review
- Evolving Role and Translation of Radiomics and Radiogenomics in Adult and Pediatric Neuro-Oncology.AJNR. American journal of neuroradiology · 2022Review
- Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy.Journal of neuro-oncology · 2021Article
- Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.Journal of clinical medicine · 2021Article
- Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET.Frontiers in oncology · 2021Article
- Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.Journal of neuro-oncology · 2019Article
- Pseudoprogression in low-grade glioma.Translational cancer research · 2019Article
- Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.Nature communications · 2019Article
- Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.Journal of neuro-oncology · 2019Article
- Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.Journal of neuro-oncology · 2019Article
- Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.Journal of magnetic resonance imaging : JMRI · 2019Review
- Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma.Clinical and translational radiation oncology · 2018Article
- Pseudoprogression in pediatric low-grade glioma after irradiation.Journal of neuro-oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
During the 6 month period following chemoradiotherapy, gliomas frequently develop new areas of contrast enhancement, which are due to treatment effect rather than tumor progression. We sought to characterize this phenomenon in oligodendrogliomas (OG) and mixed oligoastrocytomas (MOA). We reviewed the imaging findings from 143 patients with a WHO grade II or III OG or MOA for evidence of pseudoprogression (PsP) or early tumor progression. We characterized these cases for 1p/19q codeletions by FISH, IDH1 R132H mutation by immunohistochemistry, and TP53, ATRX, and EGFR mutations by next generation sequencing. We then reviewed the pathologic specimens of the patient cases in which a re-resection was performed. We found that OG and MOA that are 1p/19q intact developed PsP at a higher rate than tumors that are 1p/19q codeleted (27 vs. 8 %). Moreover, IDH1 wild-type (WT) tumors developed PsP at a higher rate than IDH1 R132H cases (27 vs. 11 %). Patients with ATRX or TP53 mutations developed PsP at an intermediate rate of 21 %. Ten patients in our cohort underwent a re-resection for early contrast enhancement; these tumors were predominantly 1p/19q intact (90 %) and had a low rate of IDH1 R132H mutation (50 %). 8 of 10 tumors demonstrated primarily treatment effects, while the remaining 2 of 10 demonstrated recurrent/residual tumor of the same grade. Early contrast enhancement that develops during the first 6 months after chemoradiotherapy is typically due to PsP and occurs primarily in OG and MOA that are 1p/19q intact and IDH WT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.